{"id":1783,"date":"2019-09-19T11:25:21","date_gmt":"2019-09-19T09:25:21","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1783"},"modified":"2024-01-10T08:48:26","modified_gmt":"2024-01-10T07:48:26","slug":"tgf-beta-and-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/tgf-beta-and-cancer\/","title":{"rendered":"TGF-beta and cancer"},"content":{"rendered":"\n

\n\t\tTGF-beta and cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The group consists of four principal investigators, whose lines of research have as a common link to advance in the knowledge of the molecular mechanisms that influence tumor cell plasticity and the tumor-stroma interactions. The group has a special interest on the role of transforming growth factor (TGF)-\u03b2 in regulating these processes, as well as on deciphering the relevance of other signaling pathways, such as epidermal growth factor (EGF) or interferon (IFN) signaling. The research is mainly focused on liver, pancreatic and skin cancer, but additional models are also being worked in collaboration with other groups.<\/p>\n

268<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"110-tgfbetacancer-fabregat-def\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t